Cordis stent gets FDA OK

Interventional technology developer Cordis Endovascular, a Johnson & Johnson subsidiary, has received Food and Drug Administration clearance for the use of its S.M.A.R.T. Nitinol stent and S.M.A.R.T. Control Nitinol stent for primary stenting of the iliac arteries.

The S.M.A.R.T. Control device is a self-expanding, crush-recoverable nitinol stent that is also cleared for the treatment of biliary obstructions. The stent delivery system includes two built-in deployment mechanisms designed to reduce unintentional stent movement during deployment, according to Cordis of Warren, NJ.

The S.M.A.R.T. Nitinol stent system is indicated for improving luminal diameter in patients with symptomatic atherosclerotic disease of the common or external iliac arteries, with angiographic evidence of a patent profunda or superficial femoral artery, according to Cordis.

By staff writers
September 5, 2003

Related Reading

Cordis files suit against Boston Scientific, January 15, 2003

Cordis debuts new biliary stent, August 27, 2002

Copyright © 2003

Page 1 of 180
Next Page